Status: Currently Official on 14-Feb-2025
Official Date: Official as of 01-Dec-2016
Document Type: USP Monographs
DocId: GUID-A546935E-0E58-4070-85E9-0647DA0998F5_1_en-US
DOI: https://doi.org/10.31003/USPNF_M1382_01_01
DOI Ref: p95jm

Captopril Compounded Oral Suspension

DEFINITION

Captopril Compounded Oral Suspension contains NLT 90.0% and NMT 110.0% of the labeled amount of captopril ($C_9H_{15}NO_3S$).

Prepare Captopril Compounded Oral Suspension 0.75 mg/mL as follows (see *Pharmaceutical Compounding—Nonsterile Preparations ⟨795⟩*).

Captopril	75 mg
Vehicle: a 1:1 mixture of Vehicle for Oral Solution (regular or sugar-free), *NF*, and Vehicle for Oral Suspension, *NF*, a sufficient quantity to make	100 mL

Place the required number of tablets in a suitable mortar and comminute to a fine powder, or use *Captopril* powder. Add 10 mL of *Vehicle*, and mix to form a uniform paste. Add the *Vehicle* in small portions, and mix thoroughly after each addition. Transfer the contents of the mortar, stepwise and quantitatively, to a calibrated bottle. Add sufficient *Vehicle* to bring to final volume, and mix well.

ASSAY

• **Procedure**

Mobile phase: Methanol and water (55:45) containing 0.5 mL/L of phosphoric acid. Filter, and degas.

Standard solution: 7.5 µg/mL of USP Captopril RS

Sample solution: Agitate the container of Oral Suspension for 30 min on a rotating mixer, remove a 5-mL sample, and store in a clear glass vial at −70° until analyzed. At the time of analysis, remove the sample from the freezer, allow it to reach room temperature, and mix with a vortex mixer for 30 s. Pipet 1.0 mL of the sample into a 100-mL volumetric flask, and dilute with *Mobile phase* to volume.

Chromatographic system

(See *Chromatography ⟨621⟩, System Suitability*.)

Mode: LC

Detector: UV 220 nm

Column: 4.6-mm × 25-cm; 5-µm packing L1

Flow rate: 1 mL/min

Injection volume: 20 µL

System suitability

Sample: *Standard solution*

[Note—The retention time for captopril is about 5.0 min.]

Suitability requirements

Relative standard deviation: NMT 0.9% for replicate injections

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of captopril ($C_9H_{15}NO_3S$) in the portion of Oral Suspension taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of USP Captopril RS in the *Standard solution* (µg/mL)

C_U = nominal concentration of captopril in the *Sample solution* (µg/mL)

Acceptance criteria: 90.0%–110.0%

SPECIFIC TESTS

• **pH ⟨791⟩:** 3.8–4.3

ADDITIONAL REQUIREMENTS

- **Packaging and Storage:** Package in tight, light-resistant containers. Store in a refrigerator.
- **Beyond-Use Date:** NMT 7 days after the date on which it was compounded when stored in a refrigerator
- **Labeling:** Label it to indicate that it is to be well shaken before use, and to state the *Beyond-Use Date*.
- **USP Reference Standards** ⟨11⟩
  USP Captopril RS

Auxiliary Information - Please check for your question in the FAQs before contacting USP.

Topic/Question	Contact	Expert Committee
CAPTOPRIL COMPOUNDED ORAL SUSPENSION	Brian Serumaga Science Program Manager	CMP2020 Compounding 2020

Chromatographic Database Information: Chromatographic Database

Most Recently Appeared In:
Pharmacopeial Forum: Volume No. PF 40(5)

Current DocID: GUID-A546935E-0E58-4070-85E9-0647DA0998F5_1_en-US

DOI: https://doi.org/10.31003/USPNF_M1382_01_01

DOI ref: p95jm